News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,819 Results
Type
Article (40010)
Company Profile (250)
Press Release (664558)
Multimedia
Podcasts (59)
Webinars (14)
Section
Business (204274)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81140)
Employer Resources (172)
FDA (16249)
Job Trends (14887)
News (345499)
Policy (32606)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1440)
Antibody-drug conjugate (ADC) (151)
Approvals (16245)
Artificial intelligence (308)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (365)
Cancer (2856)
Cardiovascular disease (212)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (497)
Cervical cancer (22)
Clinical research (66845)
Collaboration (1011)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2624)
CRISPR (56)
C-suite (324)
Cystic fibrosis (112)
Data (2991)
Decentralized trials (2)
Denatured (20)
Depression (60)
Diabetes (346)
Diagnostics (6423)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (137)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87445)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113735)
Executive appointments (845)
FDA (17892)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (928)
Gene editing (129)
Generative AI (22)
Gene therapy (372)
GLP-1 (780)
Government (4501)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (148)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (18)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (399)
Lymphoma (208)
Machine learning (11)
Management (58)
Manufacturing (383)
MASH (90)
Medical device (13461)
Medtech (13466)
Mergers & acquisitions (19576)
Metabolic disorders (847)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2115)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (427)
Opinion (217)
Ovarian cancer (101)
Pain (105)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (296)
Patient recruitment (163)
Peanut (50)
People (57681)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20827)
Phase II (29442)
Phase III (21916)
Pipeline (1626)
Policy (199)
Postmarket research (2563)
Preclinical (8869)
Press Release (64)
Prostate cancer (139)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (457)
Real estate (5917)
Recruiting (66)
Regulatory (22625)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (156)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (37)
Vaccines (778)
Venture capital (53)
Weight loss (256)
Women's health (47)
Worklife (16)
Date
Today (62)
Last 7 days (363)
Last 30 days (1868)
Last 365 days (31201)
2025 (16716)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38203)
Australia (6232)
California (7427)
Canada (2356)
China (669)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82100)
Florida (1115)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (361)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1019)
Massachusetts (5516)
Michigan (246)
Minnesota (449)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2070)
New Mexico (28)
New York (2082)
North Carolina (1078)
North Dakota (8)
Northern California (3270)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1609)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2777)
Tennessee (126)
Texas (1120)
United States (27510)
Utah (219)
Virginia (184)
Washington D.C. (72)
Washington State (630)
West Virginia (4)
Wisconsin (66)
704,819 Results for "evommune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria Demonstrating Robust Activity and Favorable Safety Profile
May 28, 2025
·
4 min read
Press Releases
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria
April 15, 2025
·
3 min read
Press Releases
Evommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patients with Atopic Dermatitis
March 17, 2025
·
3 min read
Business
Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio
Evommune, Inc. today announced it has entered into a definitive, worldwide license agreement with AprilBio Co., Ltd. (Kosdaq: 397030), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs, for an IL-18 targeted fusion protein.
June 24, 2024
·
3 min read
Business
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
Evommune, Inc. and Accutar Biotechnology Inc. today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases.
November 28, 2023
·
2 min read
Business
Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Greater China and key Asian countries
Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.
March 20, 2024
·
3 min read
Drug Development
Evommune Announces Initiation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria
Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced the initiation of its Phase 1 first-in-human study, evaluating EVO756 in heathy adults and adults with chronic spontaneous urticaria (CSU).
January 18, 2024
·
3 min read
Press Releases
Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases
November 1, 2024
·
3 min read
Press Releases
Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
September 3, 2024
·
3 min read
Business
Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan
Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan.
September 27, 2023
·
4 min read
1 of 70,482
Next
